Begonya Comin-Anduix

Dr. Begonya Comin-Anduix serves as an Adjunct Professor in the departments of Molecular and Medical Pharmacology and Surgery at the University of California, Los Angeles (UCLA) School of Medicine. Her academic journey is marked by a profound dedication to advancing the field of oncology, with a particular focus on interventional oncology and immunotherapy. Dr. Comin-Anduix's innovative research employs pigs as model organisms to explore tumor epitope immunogenicity and the intricacies of interferon receptor signaling pathways. Her work is instrumental in developing combination therapies aimed at enhancing breast cancer immunotherapy. Throughout her career, Dr. Comin-Anduix has made significant contributions to the scientific community, authoring numerous publications on critical topics such as tumor neoantigen prediction and the efficacy of immune checkpoint inhibitors. Her research delves into the genetic programming of cancer-targeted immune systems and the potential of adoptive cell transfer for tumor eradication. Additionally, she has explored the mechanisms behind drug-induced resistance in melanoma and the modulation of cell signaling networks in patients with metastatic melanoma. Dr. Comin-Anduix's research is characterized by its breadth and depth, encompassing the investigation of the immunological effects of various treatments. She is particularly interested in the impact of CTLA4 blockade and dendritic cell-based immunotherapy on the immune response. Her work also highlights the pivotal role of natural killer cells in orchestrating effective immune responses against cancer. Her commitment to advancing cancer treatment is reflected in her ongoing efforts to unravel the complexities of the immune system's interaction with tumors. By exploring novel therapeutic approaches and combination strategies, Dr. Comin-Anduix aims to improve patient outcomes and contribute to the development of more effective cancer therapies. Dr. Comin-Anduix's research not only advances scientific understanding but also holds promise for translating findings into clinical applications. Her dedication to bridging the gap between laboratory research and patient care underscores her role as a leader in the field of oncology. Through her work, she continues to inspire and mentor the next generation of researchers and clinicians, fostering a collaborative environment that drives innovation and progress in cancer treatment. In addition to her research endeavors, Dr. Comin-Anduix is actively engaged in the academic community, participating in conferences and symposia to share her insights and findings. Her contributions to the field have earned her recognition and respect among her peers, solidifying her reputation as a pioneering figure in the realm of cancer immunotherapy and interventional oncology.